- Investing.com
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company’s lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Metrics to compare | CING | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCINGPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.4x | −1.9x | −0.5x | |
PEG Ratio | −0.06 | −0.03 | 0.00 | |
Price/Book | 30.6x | 1.8x | 2.6x | |
Price / LTM Sales | - | 1.7x | 3.1x | |
Upside (Analyst Target) | 196.2% | 198.8% | 57.6% | |
Fair Value Upside | Unlock | 21.1% | 8.6% | Unlock |